Overview
Spherix’s coverage of the systemic lupus erythematosus market focuses on rheumatologists’ understanding, diagnosis, and treatment of the disease. Learnings include brand use, factors in brand selection and criteria for evaluating success.
Services Available
Exploring the patient journey
Lupus Nephritis (US)
Systemic Lupus Erythematosus (US) - annual, n=1,000 patient charts
Prepping for the pipeline
Lupus Nephritis (US)
Systemic Lupus Erythematosus (US)
Benchmarking new brand performance
Anifrolumab (AstraZeneca) in Systemic Lupus Erythematosus (US)*
Benlysta (GSK) and Voclosporin (Aurinia) in Lupus Nephritis (US)*
*Pending approvals and launch